Background: Statins reduce amyloid-β (Aβ) levels in the brain and cerebrospinal fluid (CSF) in animals and may thereby favorably alter the pathobiology of AD. It is unclear if statins modify Aβ metabolism or improve cognition in asymptomatic middle-aged adults at increased risk for AD. Methods: In a 4-month randomized, double-blind, controlled study, we evaluated the effects of simvastatin 40 mg daily vs. placebo on CSF Aβ42 levels and cognition in 57 asymptomatic middle-aged adult children of persons with AD. Results: Compared to placebo, individuals randomized to simvastatin for 4 months had similar changes in CSF Aβ42 (p = 0.344) and total tau levels (p = 0.226), yet greater improvements in some measures of verbal fluency (p = 0.024) and working memory (p = 0.015). APOE4 genotype, gender, and vascular risk factors were associated with CSF biomarker levels, but did not modify treatment effects. Conclusion: In asymptomatic middle-aged adults at increased risk for AD, simvastatin use improved selected measures of cognitive function without significantly changing CSF Aβ42 or total tau levels. Further studies are needed to clarify the impact of higher dose and/or longer duration statin therapy on not only Aβ metabolism, but also other preclinical processes related to the development of AD.
INTRODUCTION
Alzheimer's disease (AD) is a devastating illness that will affect an increasing number of older adults in the coming decades unless effective preventive strategies are developed. Hypercholesterolemia in midlife leads to an increased risk of developing AD later in life and, therefore, has been targeted as a potentially modifiable risk factor for AD [14] . While some observational studies show that use of lipid-lowering agents, specifically statins, is associated with a reduced incidence and prevalence of AD [10, 29, 41] , not all studies support these findings [25, 42] . In animal models, hypercholesterolemia stimulates amyloid-β (Aβ) deposition in the brain [26] , a pathologic hallmark of AD. Statins reduce CSF and brain Aβ42 levels in animals by 50%, suggesting that statins may modify AD risk by affecting amyloid-β protein precursor (AβPP) processing [7] . It remains unclear, however, whether statins will effectively lower CSF and brain Aβ levels in humans [12, 28, 31, 32] . Furthermore, the effects of such changes in Aβ levels on cognition are unknown.
Previous investigations support the notion that statins may have the greatest benefit when they are targeted earlier in the disease course in high risk populations. Clinical studies to date show that short-term statin therapy (3 to 12 months) may beneficially modify CSF Aβ levels [12, 31, 32] and cognition [33] in persons with mild AD, but are less effective in persons with more advanced disease [31, 33] . Persons carrying the apolipoprotein E ε4 (APOE4) allele, the main genetic risk factor for late-onset AD, may also have greater cognitive benefit from statin therapy [33] . These findings, together with the fact that it is midlife hypercholesterolemia that contributes to AD risk decades later, suggest that an optimal prevention strategy may be to target statin therapy in a middle-aged, preclinical, at-risk population with high APOE4 allele prevalence. Asymptomatic middle-aged adult children of persons with late-onset AD are ideal to study as their risk for AD is increased not only by their family history (a potential marker of unidentified genetic and/or environmental AD risk factors) [13] , but also by their high prevalence of APOE4 allele [30] .
Our study is a randomized, placebo-controlled, double-blind, parallel-group design clinical trial evaluating the effects of four months of simvastatin therapy on CSF Aβ42 levels and cognition in asymptomatic middle-aged adults with a parental history of AD and high prevalence of APOE4 genotype.
METHODS

Participants
Fifty-seven men and women without cognitive impairment were recruited from the Wisconsin Registry for Alzheimer's Prevention (WRAP), a statewide registry of adult children (ages 40-65 years) of persons with late-onset AD [30] . Prior to enrollment in WRAP, a diagnosis of definite or probable AD in one or both parents was confirmed using the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria [19] through clinical evaluation and/or chart review by physicians and neuropsychologists with expertise in the diagnosis of dementia.
WRAP registrants were eligible for participation if they did not meet any of the following exclusion criteria: current use of cholesterol-lowering medications or medications known to interact with simvastatin, liver disease, past adverse reaction to a statin drug, or elevated creatine kinase (CK). CSF samples were not collected in persons with a contraindication to lumbar puncture or who declined the procedure. This study was approved by the University of Wisconsin Human Subjects Committee and was conducted in accord with the Helsinki Declaration of 1975. Informed consent was obtained from each participant.
Study design
All data were collected at the University of Wisconsin General Clinical Research Center. Participants attended three visits during the 4-month study (baseline, month 1, and month 4). At each visit, subjects had fasting blood tests and completed a two-hour cognitive battery measuring memory, language fluency, visualmotor function, and executive function. At baseline and month 4, a lumbar puncture was performed for CSF collection.
At baseline, participants were randomized in a 1:1 ratio to receive simvastatin 40 mg nightly (n = 29) vs. matching placebo (n = 28). Randomization was conducted by the University of Wisconsin Pharmaceutical Research Center and was stratified based on APOE4 allele status (positive or negative) using a forced block design. Subjects and investigators were blinded to the identity of the study medication and to cholesterollowering effects during the course of the study. 
CSF collection
CSF samples were collected at the same time in the morning at both the baseline and month 4 visits. Subjects were placed in a sitting or lateral decubitus position and a Sprotte 20-or 22-gauge spinal needle was inserted into the L3/L4 or L4/L5 interspace using sterile technique. Approximately 10 mL of CSF were collected, aliquoted, and transported immediately for processing. CSF samples were refrigerated and shipped within 24 hours to Athena Diagnostics (Worcester, MA) for analysis of CSF Aβ42 and T-tau levels.
Laboratory evaluation
All blood tests were collected following a 12-hour fast. Glucose, CK, aspartate aminotransferase, and alanine aminotransferase levels were measured using enzymatic precipitation techniques. Fasting plasma samples were sent for NMR spectroscopy lipoprotein subclass analysis (NMR LipoProfile , LipoScience, Inc., Raleigh, NC). APOE4 allele was measured using standard PCR and DNA sequencing techniques. CSF samples were shipped to Athena Diagnostics (Worcester, MA) for analysis with ADmark Tau/Aβ42 CSF Analysis and Interpretation using capture ELISA.
Cognitive testing
Prior to lumbar puncture, cognitive testing was administered by a trained technician according to protocols established for each standardized test. Several cognitive domains were assessed, including: verbal and nonverbal memory ( [40] , and Trailmaking Tests A and B [34] ). All study personnel were blinded to study drug assignment and APOE4 allele status when administering and scoring cognitive tests.
Statistical analysis
Laboratory parameters and raw cognitive test scores were described by means and standard deviations along with their corresponding change from baseline. Changes within study groups were assessed by Wilcoxon paired signed-rank tests. Between group comparisons of values and changes for CSF biomarkers, the primary outcome, and other laboratory parameters used Wilcoxon signed-rank tests. Between group comparisons of values and changes in the cognitive tests scores were assessed using Robust Estimation Wilcoxon-score analysis of covariance (ANCOVA), adjusting for age and education. Analyses were performed using R statistical computing environment [37] . Using data from 38], a total sample size of 50 subjects should provide greater than 90% power to detect a 10% change in CSF Aβ42 in the simvastatin arm compared to placebo (two-tailed α = 0.05).
RESULTS
Baseline participant characteristics
Baseline participant characteristics (n = 57) are presented in Table 1 . CSF was obtained in 50 (88%) partic- ipants. Twenty-four (42%) participants were APOE4 allele carriers (ε2/ε4 n = 2 [8%]; ε3/ε4 n = 21 [88%]; and ε4/ε4 n = 1 [4%]). At baseline, all participants had normal cognitive function, yet 34 (68%) of participants met CSF biomarker criteria for AD according to previously established criteria [8, 21] (Table 1) . At baseline, more subjects in the placebo group were using selective serotonin reuptake inhibitors (SSRIs) than those in the simvastatin group (simvastatin 3.4% vs. placebo 21.4%, p = 0.039). Only one participant (placebo group) was currently clinically depressed (Center for Epidemiological Studies Depression Scale [CESD] [24] score > 16 points). All other subject characteristics, significant medical history, and medication use were similar in both treatment arms (all p-values > 0.1, Table 1 ).
E4-E4+
Fifty-three subjects (93%) (46 with CSF) completed the study. Reasons for withdrawal are outlined in Fig. 1 . None of the participants developed any significant laboratory abnormalities or unexpected adverse outcomes. Post-lumbar puncture headache rate was 7%.
Baseline CSF biomarker levels CSF Aβ42 and T-tau levels at baseline were directly correlated (F [1,36] = 6.10, p = 0.018) in both unadjusted and models adjusted for APOE4, vascular risk factors, and gender (Fig. 2) . At baseline, APOE4 allele carriers had similar demographic and vascular risk factor characteristics to non-carriers (data not shown, all p-values > 0.2). Compared to non-carriers, however, APOE4 carriers had significantly lower mean values of both CSF Aβ42 (APOE4 non-carriers 945.4 ± 255.2 pg/mL; carriers 727.4 ± 184.5 pg/mL, p = 0.002) and T-tau (APOE4 non-carriers 620.7 ± 288.7 pg/mL; carriers 434.0 ± 246.9 pg/mL, p = 0.006) (Fig. 3) .
Age, education, gender, and individual vascular risk factors did not correlate with CSF biomarker levels. However, gender interacted with body mass index . Thus, men with higher BMI had lower CSF Aβ42 and T-tau levels compared to men with lower BMI. BMI had little relationship to CSF biomarkers in women (Fig. 4) . Men with higher serum TC levels had lower CSF Aβ42 levels than men with normal serum TC levels, while in women this relationship was reversed (Fig. 5) . No other relationships between vascular risk factors and CSF T-tau levels were observed.
Simvastatin effects on blood and CSF biomarkers
As expected, simvastatin significantly lowered TC (−27%), low-density lipoprotein cholesterol (LDL-C) (−41%), and triglyceride levels (−27%) compared to placebo (Table 2) . In unadjusted models and models adjusted for APOE4, vascular risk factors, gender, and CSF biomarker status ("consistent with AD" or not), changes in CSF Aβ42 and T-tau levels in subjects assigned simvastatin therapy were similar to those seen in subjects on placebo (Table 2) . APOE4 genotype, CSF biomarker status ("consistent with AD" or not), and other vascular risk factors did not influence response to therapy.
Simvastatin effects on cognition
At baseline, none of the participants had cognitive impairment as demonstrated by a pattern of test scores below the 9th percentile rank. Cognitive measures (Ta-ble 3) were similar in the two treatment groups (all p > 0.1) at baseline, with the exception of the baseline score on a WMS-III Mental Control subtest [40] , on which subjects assigned to placebo outperformed those assigned to simvastatin (F [1,44] = 5.10, p = 0.029). Subjects assigned simvastatin showed greater improvements in tests of verbal fluency and working memory compared to placebo, with trends toward improvement in verbal delayed free recall and construction tasks (Table 3). At month 4, subjects on placebo were faster on a visual cancellation test compared to those on simvastatin (Table 3) . Adjusting for APOE4 genotype and baseline differences in SSRI use did not alter cognitive outcomes.
DISCUSSION
In this randomized controlled study of asymptomatic middle-aged adults at increased risk for AD, we found that subjects treated for four months with simvastatin 40 mg daily demonstrated similar changes in CSF Aβ42 and T-tau levels compared to those taking placebo, yet greater improvement on some cognitive measures of verbal fluency, working memory, verbal delayed free recall, and construction tasks. Baseline CSF Aβ42 and T-tau values were lower in APOE4 carriers compared to non-carriers, but APOE4 genotype did not affect changes in CSF biomarkers or response to therapy. While individual vascular risk factors did not significantly influence CSF Aβ42 or T-tau levels in this study, gender interacted with BMI and TC to predict baseline CSF biomarker levels and changes in biomarkers, independent of therapeutic effects. These novel, preliminary data in a unique group of at-risk adults may help guide future research investigating the effects of vascular risk factor modification on preclinical processes related to the risk of developing AD.
Statin effects on Aβ metabolism and cognition may be significantly influenced by the targeted study population. Persons with preexisting AD may be too far along in the disease process to reverse the cascade of neuronal degeneration and healthy controls at average risk for AD may not benefit from such therapies in the presence of normal AβPP processing. To date, four other prospective clinical trials have evaluated the effects of statins on CSF Aβ levels [12, 28, 31, 32] ; three of these studies focused on persons with AD [12, 31, 32] and one studied cognitively healthy, hypercholesterolemic adults at average risk for AD [28] . Of the four studies, only one included a control group [31] . Our study differs from previous investigations in that it is larger [12, 28, 31, 32] ,used a randomized placebo-controlled design [12, 28, 32] , measured domain-specific cognitive outcomes [12, 28, 31, 32] , and focused on a preclinical, middle-aged population with increased risk for AD (family history of AD and high APOE4 allele prevalence) [12, 28, 31, 32] . In an uncontrolled study of 19 persons with AD, use of simvastatin 20 mg daily for 3 months was associated with reduced concentrations of CSF α-and β-cleaved soluble AβPP (αsAβPP, βsAβPP), but not with changes in CSF Aβ42, T-tau, or phosphorylated-tau (p-tau) [32] . In contrast, a 12-month follow-up trial in 19 AD patients showed an increase in both CSF αsAβPP and p-tau following simvastatin therapy, but no effect on βsAβPP [12] As this open trial did not have a placebo group, it is unclear how these statin-associated changes compared to CSF changes noted with natural disease progression. In a 26-week randomized controlled clinical trial of 44 persons with AD, simvastatin 80 mg daily reduced CSF Aβ40 (but not Aβ42) levels in persons with mild AD, but not in those with more advanced disease, suggesting greater statin effects earlier in the disease process [31] . In an uncontrolled study of 23 hypercholesterolemic subjects without dementia (ages 34-87 years), 14 weeks of simvastatin 40 mg daily was associated with reduced CSF p-tau levels compared to pravastatin 80 mg daily, but not with significant changes in CSF T-tau, Aβ42, or Aβ40 [28] . Our study population differs from the study of asymptomatic hypercholesterolemic subjects in that our participants had fairly normal cholesterol levels and were more homogeneous in age and AD risk, potential confounding factors for changes in CSF biomarkers. Together with our find-ings, these studies suggest that future trials should use a randomized controlled design, target high risk asymptomatic adults, and investigate the effects of higher dose and/or longer duration statin therapy on not only Aβ metabolism, but also on other preclinical processes closely related to the development of AD.
Cognitive outcomes from ours and previous trials also suggest that the optimal timing for statin therapy may be in the preclinical or early disease stages, before neurodegeneration becomes irreversible. In addition, findings from ours and other studies support that domain-specific neuropsychological tests may be more sensitive in distinguishing preclinical cognitive benefits in asymptomatic persons at risk for AD compared to global measures of cognitive function. In the three previously discussed CSF studies in AD patients, statin therapy was associated with conflicting results on global cognitive measures (Mini Mental State Examination [MMSE] and Alzheimer's Disease Assessment ScaleCognitive Portion [ADAS-cog]) [12, 31, 32] . In a 12-month randomized controlled trial of 63 older adults with AD, Sparks et al. demonstrated that atorvastatin may improve cognition in older adults with AD, with the greatest cognitive benefits noted in APOE4 carriers who are early in their disease course [33] . In a study by Muldoon et al., hypercholesterolemic middleaged adults at average risk for AD were noted to have less improvement in cognition following simvastatin therapy compared to placebo [23] . In contrast, our asymptomatic at-risk participants randomized to simvastatin had improvements in domain-specific tests of verbal fluency, working memory, verbal delayed free recall, and construction tasks. The cognitive domains which improved with statin therapy in our study are similar to those measures noted to decline in asymptomatic middle-aged APOE4 carriers [3] , suggesting that statins may stabilize these vulnerable cognitive domains in this at-risk cohort with high APOE4 prevalence. Our at-risk population may be more sensitive to the beneficial cognitive effects of potential preventive therapies; however, given the modest magnitude of the cognitive changes observed in our study, longer studies are necessary to establish if these differences in cognitive test scores lead to clinically beneficial cognitive changes. Given that cognitive outcomes were an exploratory secondary aim of this trial, we did not correct for multiple comparisons. Thus, larger prospective controlled trials of longer duration are needed to confirm our preliminary findings.
Consistent with our study results, animal and clinical studies support that statins may benefit cognition independently of their effects on Aβ metabolism [16] , possibly through modifying signaling pathways, reducing inflammation, improving cerebral blood flow, and/or via more acute cholinomimetic effects [4] . Thus, some of the positive cognitive changes noted in our study may be due to some of these other unmeasured processes. While some AD-related mechanisms may be more rapidly reversed with statins, others may require longer duration of therapy. Although statins reduce CSF and brain Aβ levels in animals in as short as three weeks [7] , our study may not have been long enough to fully assess simvastatin's impact on CSF Aβ levels. Longer trials are underway investigating pleiotropic effects of statins on cognition and AD-related mechanisms of disease in at-risk adults.
Despite normal cognitive function in our participants, our findings also suggest that asymptomatic middle-aged APOE4 carriers may already exhibit pathobiological changes in Aβ metabolism compared to APOE4 non-carriers. Persons with AD have lower CSF Aβ42 and higher CSF T-tau levels than healthy controls [35] , possibly from increased Aβ deposition into amyloid plaques, reduced synthesis of Aβ by dying neurons, and intracellular release of tau into the CSF. In older adults and persons with mild cognitive impairment (MCI), lower levels of CSF Aβ42 [1, 6] and higher levels of CSF T-tau predict future risk of dementia [1] . Our findings of lower baseline CSF Aβ42 levels in asymptomatic APOE4 carriers are consistent with those noted in the BIOCARD study [36] and may suggest increased risk for future cognitive decline. However, we also surprisingly found lower CSF T-tau levels in persons at increased genetic risk for AD (APOE4 carriers) as well as in those participants with lower CSF Aβ42 levels (suggesting a possible increased risk for disease progression). Our CSF T-tau findings differ from those noted in the BIOCARD study, in which APOE4 carriers and non-carriers had similar mean CSF T-tau values [36] . While the T-tau results were unexpected, the strong association of the CSF T-tau levels with APOE4 status and Aβ levels support that further investigation is needed to clarify the longitudinal changes in CSF Aβ42 and T-tau levels spanning the preclinical phase of the disease through the development of AD. Based on previously published studies of persons with AD [8, 21] , many participants in our study had combined CSF Aβ42 and T-tau biomarker levels meeting criteria for AD despite their having normal cognitive function. Further investigation is necessary to evaluate if this combination of biomarkers predict future risk for cognitive decline in an asymptomatic middle-aged at-risk population or if such CSF measures are less accurate in this age group. Findings from large, multicenter trials such as the ongoing Alzheimer's Disease Neuroimaging Initiative (ADNI) will help clarify the natural progression of CSF biomarkers throughout the disease course and will establish the best techniques for CSF biomarker collection and analysis to optimize the accuracy of such measures [22] .
We also found that increased TC levels and BMI were associated with lower CSF Aβ42 levels in men, suggesting possible gender differences in the effects of vascular risk factors on AD progression. In general, men have more atherogenic lipid profiles than women, which could explain the gender differences noted in association with CSF Aβ42 levels; however, we did not find an association between CSF Aβ42 levels and lipoprotein markers of atherogenicity, including LDL particle number, LDL size, or HDL size. Our findings that gender and BMI interact to affect CSF biomarkers are supported by data showing a link between obesity, gender, inflammation, AβPP processing, and AD risk [11] . Further investigation is needed into the impact of dyslipidemia, obesity, and gender on the neurobiology of AD.
CONCLUSIONS
In asymptomatic middle-aged adults at increased risk for AD, treatment with simvastatin led to similar changes in CSF Aβ42 and T-tau levels compared to placebo, yet greater improvement in some cognitive measures of verbal fluency, working memory, verbal delayed free recall, and construction tasks. APOE4 genotype and the interaction of gender with BMI and TC levels influenced CSF Aβ42 and T-tau levels in this group of at-risk adults, but did not affect response to simvastatin. Further studies are needed to investigate the impact of higher dose and/or longer duration statin therapy on mechanisms related to the development of AD, including Aβ metabolism, inflammation, and cerebral perfusion. In addition, findings from the present study emphasize the need for future investigations to assess the interactive effects of gender, genetic risk, and vascular biology on preclinical AD biomarkers. Ultimately, large randomized, controlled clinical trials are needed to best assess the effects of statins on long-term cognitive outcomes and the development of AD in asymptomatic adults at high risk for the disease.
